000932715 000__ 03565cam\a2200493Ia\4500
000932715 001__ 932715
000932715 005__ 20230306151621.0
000932715 006__ m\\\\\o\\d\\\\\\\\
000932715 007__ cr\un\nnnunnun
000932715 008__ 200516s2020\\\\sz\\\\\\ob\\\\001\0\eng\d
000932715 019__ $$a1155884716$$a1156616474$$a1156745607$$a1157266450$$a1157661040$$a1158325304
000932715 020__ $$a9783030438555$$q(electronic book)
000932715 020__ $$a3030438554$$q(electronic book)
000932715 020__ $$z9783030438548
000932715 020__ $$z3030438546
000932715 0247_ $$a10.1007/978-3-030-43
000932715 0247_ $$a10.1007/978-3-030-43855-5$$2doi
000932715 035__ $$aSP(OCoLC)on1154508489
000932715 035__ $$aSP(OCoLC)1154508489$$z(OCoLC)1155884716$$z(OCoLC)1156616474$$z(OCoLC)1156745607$$z(OCoLC)1157266450$$z(OCoLC)1157661040$$z(OCoLC)1158325304
000932715 040__ $$aEBLCP$$beng$$cEBLCP$$dGW5XE$$dEBLCP$$dLQU$$dYDX$$dUPM$$dOCLCF
000932715 049__ $$aISEA
000932715 050_4 $$aRM267
000932715 08204 $$a615.7/92$$223
000932715 1001_ $$aBueno, Juan.
000932715 24510 $$aPreclinical evaluation of antimicrobial nanodrugs /$$cJuan Bueno.
000932715 260__ $$aCham :$$bSpringer,$$c2020.
000932715 300__ $$a1 online resource (125 pages).
000932715 336__ $$atext$$btxt$$2rdacontent
000932715 337__ $$acomputer$$bc$$2rdamedia
000932715 338__ $$aonline resource$$bcr$$2rdacarrier
000932715 347__ $$atext file$$bPDF$$2rda
000932715 4901_ $$aNanotechnology in the Life Sciences
000932715 504__ $$aIncludes bibliographical references and index.
000932715 506__ $$aAccess limited to authorized users.
000932715 520__ $$aTranslational medicine addresses the gap between research and the clinical application of new discoveries. To efficiently deliver new drugs to care centers, a preclinical evaluation, both in vitro and in vivo, is required to ensure that the most active and least toxic compounds are selected as well as to predict clinical outcome. Antimicrobial nanomedicines have been shown to have higher specificity in their therapeutic targets and the ability to serve as adjuvants, increasing the effectiveness of pre-existing immune compounds. The design and development of new standardized protocols for evaluating antimicrobial nanomedicines is needed for both the industry and clinical laboratory. These protocols must aim to evaluate laboratory activity and present models of pharmacokinetic-pharmacodynamic and toxicokinetic behavior that predict absorption and distribution. Likewise, these protocols must follow a theranostics approach, be able to detect promising formulations, diagnose the infectious disease, and determine the correct treatment to implement a personalized therapeutic behavior. Given the possibilities that nanotechnology offers, not updating to new screening platforms is inadequate as it prevents the correct application of discoveries, increasing the effect of the valley of death between innovations and their use. This book is structured to discuss the fundamentals taken into account for the design of robust, reproducible and automatable evaluation platforms. These vital platforms should enable the discovery of new medicines with which to face antimicrobial resistance (RAM), one of the great problems of our time.
000932715 588__ $$aDescription based on print version record.
000932715 650_0 $$aAnti-infective agents.
000932715 650_0 $$aNanomedicine.
000932715 77608 $$iPrint version:$$aBueno, Juan$$tPreclinical Evaluation of Antimicrobial Nanodrugs$$dCham : Springer International Publishing AG,c2020$$z9783030438548
000932715 830_0 $$aNanotechnology in the life sciences.
000932715 852__ $$bebk
000932715 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-030-43855-5$$zOnline Access$$91397441.1
000932715 909CO $$ooai:library.usi.edu:932715$$pGLOBAL_SET
000932715 980__ $$aEBOOK
000932715 980__ $$aBIB
000932715 982__ $$aEbook
000932715 983__ $$aOnline
000932715 994__ $$a92$$bISE